PSA y hK2 en el diagnóstico de cancer de próstata.

Autores de IIS La Fe

• José Miguel Alapont Alacreu

  Autor

• Silvia Navarro Rosales

  Autor

• Alberto Budía Alba

  Autor

• Francisco España Furio

  Autor

• Jose Francisco Morera Martinez

  Autor

• Juan Fernando Jimenez Cruz

  Autor

Grupos

• Hemostasia, Trombosis, Arteriosclerosis y Biología vascular

Abstract

Serum markers for prostate carcinoma are widely applied for the purpose of early detection of cancer and the differentiation between benign and malignant disease, for the pre-treatment staging of detected prostatic cancers, and for the monitoring of prostate cancer after curative or palliative therapies. Since its discovery in 1979, serum PSA has been the most powerful marker of prostate cancer, but, when used alone, PSA is not sufficiently sensitive or specific to consider it an ideal tool for the early detection or staging of prostate cancer. To optimize the use of PSA, the concepts of PSA velocity, PSA density, and age-related PSA values were developed. Moreover, the molecular forms of PSA, especially the percentage of free PSA, seem to be useful tools for the detection of prostate cancer in men with slightly elevated total PSA. Human kallikrein 2 (hK2), a serine protease closely related to PSA that also is expressed predominantly in the prostate, is a new complementary marker to PSA for early detection of prostate cancer. In this review, we examine PSA testing and its effectiveness in the diagnosis of prostate cancer. Further, we also evaluate recent literature regarding the use of hk2.